Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATReceivables - Net
Ratios

Alaunos Therapeutics (TCRT) Leases (2019 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Leases for 10 consecutive years, with $1.0 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Leases fell 53.76% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Sep 2023, down 53.76%, and an annual FY2022 reading of $2.1 million, down 51.67% over the prior year.
  • Leases was $1.0 million for Q3 2023 at Alaunos Therapeutics, down from $1.4 million in the prior quarter.
  • Across five years, Leases topped out at $5.4 million in Q2 2021 and bottomed at $1.0 million in Q3 2023.
  • Average Leases over 5 years is $2.8 million, with a median of $2.2 million recorded in 2022.
  • The sharpest move saw Leases soared 185.24% in 2021, then crashed 56.61% in 2022.
  • Year by year, Leases stood at $1.3 million in 2019, then surged by 262.43% to $4.6 million in 2020, then fell by 4.95% to $4.4 million in 2021, then tumbled by 51.67% to $2.1 million in 2022, then crashed by 51.36% to $1.0 million in 2023.
  • Business Quant data shows Leases for TCRT at $1.0 million in Q3 2023, $1.4 million in Q2 2023, and $2.0 million in Q1 2023.